Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts

References

• Frohman EM, Frohman TC, Zee DS, et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005;4:111-121
   PubMed Web of Science ®Google Scholar
• Frohman EM. Multiple sclerosis. Med Clin North Am 2003;87:867-897, viii-ix
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis International Federation. About MS: what is MS? Accessed October 6, 2008. http://www.msif.org/en/about_ms/what_is_ms.html
   Google Scholar
• National Multiple Sclerosis Society. About MS: who gets MS? Accessed October 6, 2008. Available at http://www.nationalmssociety.org/about-multiple-sclerosis/who-gets-ms/index.aspx
   Google Scholar
• Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002;58:136-138
   PubMed Web of Science ®Google Scholar
• Richards RG, Sampson FC, Beard SM, et al. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002;6:1-73
   PubMedGoogle Scholar
• Multiple Sclerosis International Federation. About MS: introduction. Accessed October 6, 2008. http://www.msif.org/en/about_ms/index.html
   Google Scholar
• Parkin D, Jacoby A, McNamee P, et al. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry 2000;68:144-149
   PubMed Web of Science ®Google Scholar
• Murphy N, Confavreux C, Haas J, et al. Quality of life in multiple sclerosis in France, Germany and the United Kingdom. Cost of Multiple Sclerosis Study Group. J Neurol Neurosurg Psychiatry 1998;65:460-466
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis International Federation. About MS: recognised treatment for MS. Accessed October 6, 2008. http://www.msif.org/en/about_ms/recognised_treat.html
   Google Scholar
• Tullman MJ, Lublin FD, Miller AE. Immunotherapy of multiple sclerosis—current practice and future directions. J Rehabil Res Dev 2002;39:273-286
   PubMedGoogle Scholar
• Pohlman CH, Uitdehaag BM. Drug treatment of multiple sclerosis. BMJ 2000;321:490-494
   PubMedGoogle Scholar
• Calabresi P. Investigating glatiramer acetate for relapsing-remitting multiple sclerosis at the double dose—is more better? Nat Clin Pract Neurol 2007;3:540-541
   PubMedGoogle Scholar
• Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006;12:309-320
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50:701-708
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294
   PubMed Web of Science ®Google Scholar
• Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacother 2001;2:1149-1165
   PubMedGoogle Scholar
• Davis WM. Multiple sclerosis: continuing mysteries and current management. Drug Topics 2000;144:93-102
   Google Scholar
• Vallittu AM, Peltoniemi J, Elovaara I, et al. The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients. Acta Neurol Scand 2005;112:234-237
   PubMed Web of Science ®Google Scholar
• Prosser LA, Kuntz KM, Bar-Or A, et al. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 2004;7:554-568
   PubMed Web of Science ®Google Scholar
• Chilcott J, McCabe C, Tappenden P, et al. Modeling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ 2003;326:522-525
   PubMed Web of Science ®Google Scholar
• Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009;15:543-555
   PubMed Web of Science ®Google Scholar
• Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of 4 immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007;13:245-261
   PubMed Web of Science ®Google Scholar
• Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. Curr Opin CNS Drugs 2004;18:561-574
   PubMed Web of Science ®Google Scholar
• Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
   PubMed Web of Science ®Google Scholar
• Morrow T. The costs and consequences of multiple sclerosis relapses: a managed care perspective. J Neurol Sci 2007;256:S39-44
   PubMed Web of Science ®Google Scholar
• Ollendorf D, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 2002;8:469-476
   PubMedGoogle Scholar
• Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-808
   Web of Science ®Google Scholar
• Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71:129-135
   PubMed Web of Science ®Google Scholar
• National Multiple Sclerosis Society. About MS: epidemiology of MS. Accessed October 8, 2008. Available at http://www.nationalmssociety.org/about-multiple-sclerosis/who-gets-ms/epidemiology-of-ms/index.aspx
   Google Scholar
• Marrie R, Horwitz R, Cutter G, et al. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler 2008;14:1091-1098
   PubMed Web of Science ®Google Scholar
• Miller A. Paroxysmal disorders. In Burkes JS, Johnson KP, eds. Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation. New York: Demos Medical Publishing, 382
   Google Scholar
• Pöllmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs 2008;22:291-324
   PubMed Web of Science ®Google Scholar
• Patten SB, Francis G, Metz LM, et al. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler 2005;11:175-181
   PubMed Web of Science ®Google Scholar
• Biogen, Inc. Medication guide: Avonex – interferon beta-1a. Published January 31, 2003. Available at http://www.fda.gov/cder/foi/label/2003/ifnbbio013103mg.pdf
   Google Scholar
• Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®). Eur J Neurol 2005;12:425-431
   PubMed Web of Science ®Google Scholar
• Carra A, Onaha P, Sinay V, et al. A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. Eur J Neurol 2003;10:671-676
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000;6:255-266
   PubMed Web of Science ®Google Scholar
• Clanet M, Kappos L, Hartung HP, et al. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose Comparison Study. Mult Scler 2004;10:139-144
   PubMed Web of Science ®Google Scholar
• Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007;13:44-52
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Atherley D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the USA. Neurology 2006;66:1696-1702
   PubMed Web of Science ®Google Scholar
• Whetten-Goldenstein K, Sloan FA, Goldenstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-425
   PubMedGoogle Scholar
• i3. Data assets: better data matters. Accessed October 8, 2008. http://www.i3global.com/DataAssets/
   Google Scholar